The experimental drug cocktail with antibodies of the company “AstraZeneca” manages to reduce severe illness or death in non-hospitalized patients with COVID-19, show results in a study at a late stage, said the British drug manufacturer, quoted by WORK.
The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial. https://t.co/nHTr9D3oTY
— Rappler (@rapplerdotcom) October 11, 2021
The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50% in patients who had symptoms for seven days or less, thus meeting the main purpose of the study.
“Early intervention with our antibody cocktail can significantly reduce the progression of severe disease, with long-term protection for more than six months,” said Mene Pangalos, executive vice president of biopharmaceutical research and development at AstraZeneca.
The company will discuss the data with the health authorities, AstraZeneca added, but without providing more specific details.
AstraZeneca is also developing a cocktail as a therapy to protect people who do not have a strong enough immune response to COVID-19 vaccines.
Last week, the company sought urgent approval from US regulators for the use of this coronavirus preventative drug.